Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Hematological Oncology · Published 2026-05-01 · DOI 10.1002/hon.70201

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1002/hon.70201

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Low‐Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T‐Cell Acute Lymphoblastic Leukemia: A Case Series · Hematological Oncology · 2026 · Same journal
• Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines · Hematological Oncology · 2026 · Same journal
• Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients · Hematological Oncology · 2026 · Same journal
• Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study · Hematological Oncology · 2026 · Same journal
• Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study · Hematological Oncology · 2026 · Same journal
• Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia · Hematological Oncology · 2026 · Same journal
• Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy · Hematological Oncology · 2026 · Same journal
• Clinical Significance of FLT3‐ITD Variation Allele Frequency in Acute Myeloid Leukemia: A Multicenter Study · Hematological Oncology · 2026 · Same journal
• Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T‐Cell Infusion: A Case Report With Mechanistic Insight · Hematological Oncology · 2026 · Same journal
• Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study · Hematological Oncology · 2026 · Same journal